Animals were treated with Tolvaptan (TOL) 10 mg/kg/d, orally for 22 days with concomitant administration of CP 75 mg/kg i.p. on days 3, 4, 5, 19, 20, and 21 of the experiment.
Treatment with TOL resulted in significant improvement in the level of urine volume, urinary creatinine, and significant reduction of body weight, serum creatinine, urea, serum potassium, urine osmolarity. TOL resulted significant reduction of blood pressure and offered protection to the heart and kidney. TOL administration significantly decreased the level of caspase-3 and Bax with increased expression of antiapoptotic Bcl-2 in renal tissue.
Animals were treated with Alogliptin (ALO) 20 mg/kg/day; p.o. for 7 days with single CP 200 mg/kg; i.p. injection on day 2.
Treatment with ALO declined serum kidney function markers, oxidative stress and apoptosis markers, MAP3K expression, phospho (p)-SMAD3, p-JNK, and p-c-Jun levels.
Alogliptin (ALO), Cyclophosphamide (CP), decapentaplegic homolog 3 (SMAD3), c-Jun N-terminal kinase (JNK), mitogen-activated protein kinase (MAPK), number of animals used (n), and Tolvaptan (TOL).
